Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “CytomX Therapeutics, Inc.”

62 pharma patents match "CytomX Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 62
Index total 30,257
Page 1 / 3

Quick answer

This filtered view shows 62 pharmaceutical patents matching "CytomX Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

62 results for “CytomX Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 12428470

    Compositions containing activatable antibodies

    CytomX Therapeutics, Inc. · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  2. US 12139543

    Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFR

    CytomX Therapeutics, Inc. · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted
  3. US 12049505

    Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  4. US 11992528

    Compositions and methods for conjugating activatable antibodies

    CytomX Therapeutics, Inc. · Granted May 28, 2024 · Expires May 23, 2044

    granted
  5. US 11952427

    Anti-CD40 antibodies and uses thereof

    CytomX Therapeutics, Inc. · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  6. US 11890354

    Activatable antibodies that bind epidermal growth factor receptor and methods thereof

    CytomX Therapeutics, Inc. · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  7. US 11884746

    Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  8. US 11867695

    Compositions and methods for detecting protease activity in biological systems

    CytomX Therapeutics, Inc. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  9. US 11859010

    Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  10. US 11814410

    Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Nov 14, 2023 · Expires Nov 9, 2043

    granted
  11. US 11802158

    Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same

    CytomX Therapeutics, Inc. · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted
  12. US 11753466

    Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted
  13. US 11667687

    Masked activatable interferon constructs

    CytomX Therapeutics, Inc. · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted
  14. US 11548943

    Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  15. US 11548944

    Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  16. US 11472875

    Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted
  17. US 11472889

    Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted
  18. US 11306149

    Anti-CD40 antibodies and uses thereof

    CytomX Therapeutics, Inc. · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted
  19. US 11267896

    Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted
  20. US 11180562

    Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-related disorder by administering activatable EGFR-binding antibodies

    CytomX Therapeutics, Inc. · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted
  21. US 11174316

    Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted
  22. US 11168144

    Activatable anti-PDL1 antibodies, and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted
  23. US 11161906

    Multispecific antibodies, multispecific activatable antibodies and methods of using the same

    CytomX Therapeutics, Inc. · Granted Nov 2, 2021 · Expires Oct 28, 2041

    granted
  24. US 11117968

    Activatable anti-CTLA-4 antibodies and uses thereof

    CytomX Therapeutics, Inc. · Granted Sep 14, 2021 · Expires Sep 9, 2041

    granted